Knowledge Center

Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus’ INTERCEPT Blood System

January 28th, 2015, Ash Stevens manufacturing facility in Riverview, Michigan approved by FDA for the manufacture of Amotosalen, the API in Cerus Corporation's INTERCEPT Blood System. 

View PDF for full details